Skip to content

Study · Not a test of the peptide alone · 2018

6 results

Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients.

Du D, Song T, Dai H, Jing Z, Chen P, Wu S

Oncoimmunology9 Apr 2018Cited by 13 (Europe PMC)

PMID30221039 (opens in a new tab)PMCIDPMC6136866 (opens in a new tab)DOI10.1080/2162402x.2018.1450128 (opens in a new tab)PepBankPUB-30221039
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma, SBRT with thymosin alpha‑1 gave a partial response in other lesions in three patients (9.7%).

    In plain wordsIn people with advanced esophageal cancer, radiation plus thymosin alpha‑1 shrank other tumor sites in three patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePartial response of non-irradiated metastatic lesions
    Study

    n = 31

    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Partial response
    9.7%
    other metastatic lesions

    Source sentences

    Summary
    Partial response occurred in three (9.7%) patients, and 11 (35.5%) patients had stable metastatic disease, which yielded a metastatic-lesion control rate of 45.2%.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma, SBRT with thymosin alpha‑1 gave a metastatic-lesion control rate of 45.2%.

    In plain wordsIn people with advanced esophageal cancer, radiation plus thymosin alpha‑1 controlled other tumor sites in 45.2% of patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMetastatic-lesion control rate
    Study

    n = 31

    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Metastatic-lesion control rate
    45.2%
    other metastatic lesions

    Source sentences

    Summary
    Partial response occurred in three (9.7%) patients, and 11 (35.5%) patients had stable metastatic disease, which yielded a metastatic-lesion control rate of 45.2%.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma treated with SBRT and thymosin alpha‑1, 54.8% of patients had progressive disease in other metastatic lesions.

    In plain wordsIn people with advanced esophageal cancer given radiation plus thymosin alpha‑1, other tumor sites kept growing in 54.8% of patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableProgressive disease in other metastatic lesions
    Study

    n = 31

    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Progressive disease
    54.8%
    other metastatic lesions

    Source sentences

    Summary
    Seventeen (54.8%) patients were documented to have progressive disease in other metastatic lesions.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma, median overall survival with SBRT and thymosin alpha‑1 was 5.2 months.

    In plain wordsIn people with advanced esophageal cancer given radiation plus thymosin alpha‑1, median survival was 5.2 months.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMedian overall survival
    Study

    n = 31

    Analysis
    Secondary
    Outcome group
    Mortality · Cancer

    Measurements

    Median overall survival
    5.2 months
    all patients

    Source sentences

    Summary
    The median overall survival and abscopal progression free survival (APFS) times were 5.2 and 2.9 months, respectively.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma, median abscopal progression-free survival with SBRT and thymosin alpha‑1 was 2.9 months.

    In plain wordsIn people with advanced esophageal cancer given radiation plus thymosin alpha‑1, tumor sites outside the radiation field progressed after a median of 2.9 months.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableMedian abscopal progression-free survival
    Study

    n = 31

    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer

    Measurements

    Median abscopal PFS
    2.9 months
    all patients

    Source sentences

    Summary
    The median overall survival and abscopal progression free survival (APFS) times were 5.2 and 2.9 months, respectively.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In heavily pretreated metastatic esophageal squamous cell carcinoma, toxicity of SBRT with thymosin alpha‑1 was acceptable and no grade 4 acute toxicity occurred.

    In plain wordsIn people with advanced esophageal cancer, radiation plus thymosin alpha‑1 caused acceptable side effects and no grade 4 acute toxicity.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTreatment-related toxicity
    Study

    n = 31

    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer

    Source sentences

    Summary
    Treatment-related toxicity was acceptable, and no grade 4 acute toxicity occurred.
    2 context sentences
    Summary · context
    Thirty-one patients with at least 2 metastatic sites were enrolled.
    Summary · context
    Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.